Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Rua Bioscience (RUA) / HY22

Operating cash burn nearly doubled to $3.7m before first revenue

Headline cash fell from $19.2m to $2.3m as Rua moves to commercialisation, with the loss widening only modestly.

Healthcare / Medicinal cannabis

RUA metric context

Comparable chart history for this briefing.

Not enough chartable history yet. This panel will populate as comparable periods are published.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 8 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$10.2m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not available for this company right now.

EPS

Not available

i

Not available for this company right now.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not available for this company right now.

P/FCF

Not available

i

Not available for this company right now.

P/B

1.74x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
25 February 2022
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY22 vs HY21

Revenue

$0.36m

+33.8% ↑ vs $0.27m

Net profit after tax

−$2.5m

+99.9% ↑ vs −$2.3b

Net cash inflow from operating activities

−$3.7m

-88.8% ↓ vs −$2m

Operating profit

−$3.9m

+99.9% ↑ vs −$3.5b

Profit before tax

−$3.5m

+99.9% ↑ vs −$3.2b

Cash and cash equivalents

$2.3m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Total assets

$28m

-12.8% ↓ vs $32.1m

What changed

For a still pre-commercial medicinal cannabis issuer, the most consequential movement is on the cash line, not the income statement

Operating outflows nearly doubled to $3.7m from $1.9m in HY21, and the headline cash balance fell to $2.3m from $19.2m a year earlier. Total assets only declined by roughly $4.1m to $28.0m over the same window, which means a large portion of the cash drawdown is reclassification within current assets (likely term deposits) rather than economic depletion of that scale.

The income statement remains pre-commercial in character. Revenue rose to $0.36m from $0.27m, but the recognition basis is not consistent across the two periods (prior was disclosed as "other income"), so the apparent uplift is not analytically clean. Loss before tax widened to $3.5m from $3.2m and loss after tax to $2.5m from $2.3m. Capex fell to $0.3m from $1.1m.

What matters

Cash burn pace stepped up materially while still pre-revenue

  • Operating cash outflow of $3.7m for the half is the more reliable read on quarterly run-rate spend than the reported loss, because the loss includes non-cash items and the company is not yet generating commercial revenue to offset operating costs. Combined with $0.3m of capex, free cash outflow pre-lease was $4.0m for the half. This matters because Rua's funding capacity, not its accounting loss, governs how long the commercialisation push can run before another capital event.

  • Liquidity disclosure needs interpretation. Headline cash of $2.3m looks tight in isolation, but total assets of $28.0m and equity of $26.5m, alongside an NTA per share of $0.16, suggest the bulk of IPO proceeds remain on the balance sheet in non-cash form. The investor read hinges on what portion of the $25.8m non-cash asset base is genuinely liquid versus tied up in plant, inventory build, intangibles, or restricted balances.

  • Commercialisation narrative still forward-looking. Management frames the period as "constructive" with "first product, first revenue imminent". That language is unchanged in tone from prior releases, so the half does not yet contain a step-change to commercial-stage economics. The result must be judged against the readiness milestones rather than against operating margins or returns.

Expectations

No quantitative targets or forward guidance are supplied, and no second-half shape framework is available for a company that was effectively pre-revenue in FY21

There is therefore nothing in this release to test against a prior numerical commitment.

What the release does support is that Rua remains in build-and-spend mode: opex has risen, capex is moderating after the prior period's plant investment, and revenue is not yet at a level that informs unit economics. What it does not support is any assessment of gross margin, recurring versus milestone mix, or the durability of demand, because those data do not yet exist at scale.

Quality of result

Earnings quality is not a meaningful frame at this stage of the business

The reported loss is a function of pre-commercial operating spend and R&D, not of working-capital movements, one-off items, or accounting choices that could be reversed. The lack of an EBITDA disclosure and the absence of segment reporting are consistent with that pre-commercial status. There is no tax distortion concern of practical relevance, because the operating loss is the dominant signal.

The cash-flow read is the more important quality signal and it has deteriorated. Operating outflows rose materially while revenue did not, so the cash-burn ratio per dollar of revenue is not yet a useful operating metric. Capex restraint at $0.3m is a partial offset, but free cash outflow pre-lease still widened to $4.0m. The release does not provide a bridge between the $16.9m fall in headline cash and the $4.0m of free cash outflow, which is the single largest gap between reported numbers and intuitive interpretation in this result.

Unresolved

Open questions

How much of the $25.8m of non-cash assets is held as term deposits or other readily liquid instruments, and what is the company's total liquidity position?
What is the expected cash burn run-rate for the next two halves, and at what point does management expect commercial revenue to cover operating costs?
When are the first commercial shipments and recognised revenues now scheduled, and what volumes and price points are assumed?
Is a further capital raise contemplated within the next twelve months, and on what trigger?
What is the basis change between HY21 "other income" and HY22 "revenue from continuing operations", and does any of the current $0.36m represent genuine third-party product sales?

This briefing cannot assess Rua's commercial-stage unit economics, gross margin profile, or runway with precision, because the release does not disclose the liquidity composition behind the $2.3m headline cash figure or the timing and pricing of first commercial sales.

Chat

Ask about RUA HY22

Ask follow-up questions about Rua Bioscience's HY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RUA HY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Rua Bioscience's HY22 result.

How much of the $25.8m of non-cash assets is held as term deposits or other readily liquid instruments, and what is the company's total liquidity position?Why does "Cash burn pace stepped up materially while still pre-revenue" matter?How strong was the cash and earnings quality in HY22?What should I watch next for RUA after HY22?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Results Announcement

HY22 / results announcement↗

Rua Bioscience Interim Financial Statements Market Announcement

HY22 / results release↗

Rua Bioscience Limited Interim Financial Statements - 31 December 2021

HY22 / financial report↗

Prior comparable period

Results Announcement

HY21 / results announcement↗

Rua Bioscience Interim Financial Statements

HY21 / financial report↗

Rua Bioscience Interim Financial Statements Market Announcement

HY21 / results release↗

Full-year context

Financial Results Announcement FY21

FY21 / results announcement↗

Rua Bioscience FY21 Annual Results Market Announcement

FY21 / results release↗

Rua Bioscience Limited FY21 Financial Statements

FY21 / financial report↗

Release context

Presentation Slides

HY22 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 2.3pp, with a distortion flag in the result.

→

Revenue growth context

Revenue growth was 33.8% for this reporting period.

→

ROE and capital efficiency

ROE was -9.3%, -1.8pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when RUA publishes next

Get the next Rua Bioscience briefing and related NZX reporting-season updates by email.